Augmentation of radiation response with the vascular targeting agent ZD6126

This publication has 23 references indexed in Scilit:

• The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors
  International Journal of Radiation Oncology*Biology*Physics, 2005
• Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy
  Cancer Research, 2005
• Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice
  International Journal of Radiation Oncology*Biology*Physics, 2005
• ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy
  Clinical Cancer Research, 2004
• Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells
  International Journal of Radiation Oncology*Biology*Physics, 2004
• Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways
  Hematology/Oncology Clinics of North America, 2004
• Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126
  Clinical Cancer Research, 2004
• Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis
  Science, 2003
• Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotheraphy
  International Journal of Radiation Oncology*Biology*Physics, 2001
• Angiogenic Factors
  Science, 1987